Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: A decision analysis

American Journal of Gastroenterology

Volumn 108, Issue 9, 2013, Pages 1486-1495

  Nguyen, Geoffrey C ^a,b,c,d   Bernstein, Charles N ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANALYSIS; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEEP VEIN THROMBOSIS; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MARKOV DECISION ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REMISSION; SENSITIVITY ANALYSIS; TREATMENT DURATION; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; QUALITY-ADJUSTED LIFE YEARS; RISK; VENOUS THROMBOEMBOLISM;

EID: 84883743541     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.220     Document Type: Article

References (32)

1. Bernstein CN , Blanchard JF , Houston DS et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with Inflammatory bowel disease: a population-based cohort study. Th romb Haemost 2001 ; 85 : 430-4.
2. Grainge MJ , West J , Card TR. Venous thromboembolism during active disease and remission in Inflammatory bowel disease: a cohort study. Lancet 2010 ; 375 : 657-63.
3. Novacek G , Weltermann A , Sobala A et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010 ; 139 : 779-87.
4. Kearon C , Akl EA , Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9Thed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012 ; 141 : e419S-94S.
5. Sam JJ , Bernstein CN , Razik R et al. Physicians ' perceptions of risks and practices in venous thromboembolism prophylaxis in Inflammatory bowel disease. Dig Dis Sci 2013 ; 58 : 46-52.
6. Arias E. United States life tables , 2007. National Center for Health Statistics, Hyattsville, MD, USA , 2011 , pp 1-60.
7. Dentali F , Douketis JD , Gianni M et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007 ; 146 : 278-88.
8. Schulman S , Granqvist S , Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997 ; 336 : 393-8.
9. Kearon C , Gent M , Hirsh J et al. A comparison of three months of anticoagulation wiThextended anticoagulation for a fi rst episode of idiopathic venous thromboembolism. N Engl J Med 1999 ; 340 : 901-7.
10. Kearon C , Ginsberg JS , Kovacs MJ et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003 ; 349 : 631-9.
11. Shen J , Ran ZH , Tong JL et al. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007 ; 26 : 653-63.
12. Carrier M , Le GG , Wells PS et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010 ; 152 : 578-89.
13. D ' Haens G , Baert F , van AG et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 ; 371 : 660-7.
14. Saini SD , Waljee AK , Higgins PD. Cost utility of infl ammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012 ; 10 : 1143-51.
15. Waljee AK , Higgins PD , Waljee JF et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol 2011 ; 106 : 794-9.
16. Gregor JC , McDonald JW , Klar N et al. An evaluation of utility measurement in crohn's disease. Infl amm Bowel Dis 1997 ; 3 : 265-76.
17. Locadia M , Bossuyt PM , Stalmeier PF et al. Treatment of venous thromboembolism with vitamin K antagonists: patients ' health state valuations and treatment preferences. Th romb Haemost 2004 ; 92 : 1336-41.
18. Pishko AM , Smith KJ , Ragni MV. Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-Effectiveness analysis from a US perspective. Th romb Haemost 2012 ; 108 : 303-10.
19. From US Bureau of Labor Statistics. Available at: http://www.bls.gov/ data/, Accessed 19 November 2012.
20. RED BOOK Online. Accessed 19 November 2012.
21. American Medical Association CodeManager Online. Available at: https://ocm.ama-assn.org/OCM/CPTRelativeValueSearch.do?submitbutton=accept , Accessed 19 November 2012.
22. Kappelman MD , Rifas-Shiman SL , Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008 ; 135 : 1907-13.
23. Razik R , Bernstein CN , Sam J et al. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized Inflammatory bowel disease patients. Can J Gastroenterol 2012 ; 26 : 795-8.
24. Papay P , Miehsler W , Tilg H et al. Clinical presentation of venous thromboembolism in Inflammatory bowel disease. J Crohns Colitis 2012 (e-pub ahead of print).
25. Solem CA , Loftus EV , Tremaine WJ et al. Venous thromboembolism in Inflammatory bowel disease. Am J Gastroenterol 2004 ; 99 : 97-101.
26. Talbot RW , Heppell J , Dozois RR et al. Vascular complications of Inflammatory bowel disease. Mayo Clin Proc 1986 ; 61 : 140-5.
27. Miehsler W , Reinisch W , Valic E et al. Is Inflammatory bowel disease an independent and disease specifi c risk factor for thromboembolism? Gut 2004 ; 53 : 542-8.
28. Kane SV , Cohen RD , Aikens JE et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 ; 96 : 2929-33.
29. Higgins P , Yang M , Chao J et al. Biologic use is associated with a major reduction in venous thromboembolic events compared with steroid use in the treatment of Inflammatory bowel disease. Am J Gastroenterol 2011 ; 106 : S449.
30. Herrinton LJ , Liu L , Fireman B et al. Time trends in therapies and outcomes for adult Inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009 ; 137 : 502-11.
31. Prandoni P , Lensing AW , Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996 ; 125 : 1-7.
32. Lee S , Mullin R , Blazawski J et al. Cost-Effectiveness of apixaban compared with warfarin for stroke prevention in atrial fi brillation. PLoS One 2012 ; 7 : e47473.